Endometrial adenocarcinoma

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
3 Unique sponsors
7 Unique IMPs
3 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
— ATC code not specified 2
A Gastroenterology (ATC A) 1
G Urology/Gynaecology (ATC G) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Kinase inhibitor 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Phase II: 1 Phase I/II: 1 Phase I (First in Human): 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase II

1 trial
  • University College Dublin Academic
    LEVONORGESTREL; TIRZEPATIDE
    2025-523877-40-00 1 country n=78
    Pending

Phase I/II

1 trial
  • Amgen Inc. Commercial
    BEMARITUZUMAB
    2023-505455-44-00 15 countries 2022 n=300
    Ended

Phase I (First in Human)

2 trials
  • Salubris Biotherapeutics Inc. Commercial
    JK08; LENVATINIB; PEMBROLIZUMAB
    2024-511750-53-00 2 countries 2022 n=130
    Ended
  • Salubris Biotherapeutics Inc. Commercial
    JK06
    2024-512421-92-00 2 countries 2025 n=305
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Salubris Biotherapeutics Inc. Commercial 2 Phase I (First in Human) 1
Amgen Inc. Commercial 1 Phase I/II 0
University College Dublin Academic 1 Phase II 0
New trials by year
2022
2
2025
1
← All indication landscapes